[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alcohol-associated-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alcohol-associated-liver-disease":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,76,100,132,152,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645066","pomegranate-dietary-supplements-in-aud-and-ald-100645066",false,"NCT07678567","Pomegranate Dietary Supplements in AUD and ALD","Supplementation of Pomegranate Dietary Supplements and Characterization of Urolithin Metabotypes in Patients With Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD)","Healthy Group:\n\nInclusion: Healthy individuals, Exclusion: AUD, ALD, AC, and inflammatory conditions,\n\nAlcohol Use Disorder Group:\n\nInclusion: AUD diagnosis Exclusion: alcohol-associated systemic conditions\n\nAlcohol-associated liver disease Group:\n\nInclusion: early-stage ALD comorbid with AUD Exclusion: Only AUD or AUD with AC\n\nAlcohol-associated cirrhosis Inclusion: AC with AUD Exclusion: AUD, and early stage ALD, as well as determined by the study cohort criteria",true,"ALL","18 Years",{"count":20,"type":21},144,"ESTIMATED","OBSERVATIONAL","The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements. Recent publications have reported that urolithins are the major active metabolites responsible for the beneficial effects of eating pomegranates, berries, or walnuts. However, the production of urolithins from the parent compound ellagic acid (EA) is dependent upon the presence of certain bacteria in the human gut. In this trial, we propose to investigate variations in gut microbiota and their capacity to metabolize pomegranate dietary supplements (PDS) into active urolithins. We will measure the levels of urolithins in blood as well as inflammatory cytokines in plasma samples upon consumption of PDS.",[25,26,27,28],"Alcohol Use Disorder","Alcohol-associated Liver Disease","Alcoholic Cirrhosis","Healthy",[30],"Pomeragranate, AUD, ALD","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":21},"2027-01-01",{"date":39,"type":21},"2032-12-31",{"name":41,"class":42},"University of Louisville","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100552429","addictological-intervention-in-liver-transplantation-recipients-100552429","NCT06472973","ADDICTOlogical Intervention in LIVEr Transplantation Recipients","AddictoLIVE","Inclusion Criteria:\n\n* Aged 18 years or above\n* Hospitalized for LT for AALD as primary, secondary or tertiary indication\n* Discharged from intensive care unit to hepatology or surgery wards\n\nExclusion Criteria:\n\n* Severe alcohol-associated hepatitis as primary indication for liver transplantation\n* Impossibility of patient follow up over the next 2 years\n* General criteria:\n\n  * Refusal or absence of informed consent,\n  * Non-affiliation to the French national health insurance,\n  * Persons placed under legal protection, guardianship or curatorship",{"count":52,"type":21},720,"INTERVENTIONAL",[55],"NA","Transplantation for end-stage-liver disease (ESLD) in the context of Alcohol-Associated Liver Disease (AALD) has been increasing and represents the main indication for Liver Transplantation (LT) in the world. Alcohol Use Disorder (AUD) is considered a brain chronic disease and requires a transdisciplinary approach that includes medical treatment and behavioral interventions.\n\nIn the context of LT, alcohol relapse occurs in 26 % up to 50% of LT recipients. Among Liver transplant recipients for AALD, severe alcoholic relapse (defined as more than 3 alcoholic drinks per day for women and 4\u002Fday for men) after LT leads to impaired longterm survival due to recurrent alcoholic cirrhosis (RAC), cardiovascular events and de novo cancer.\n\nSeveral strategies have been developed to prevent alcohol relapse. After LT, integrating an addiction team into the LT program has been advocated by the latest guidelines in Europe and the United States, in order to bring the management of alcohol-use disorder (AUD) in transplantation units, through the association of psychosocial and pharmacological interventions previously reported in AALD. However, those guidelines were based on descriptive studies, and the effect of this management needs to be confirmed through a randomized, controlled, multicenter study, involving centers that still do not include an addiction team in their LT programs.\n\nThis study will therefore assess prospectively and comparatively the impact of an addiction intervention after LT on return to alcohol use rates. We hypothesize that standardized targeted addiction monitoring of Liver Transplant recipients decreases the rates of alcohol relapse two years post-liver transplantation.",[58,59],"Alcohol Associated Liver Disease","Liver Transplantation",[61,62,63,64],"Liver transplantation","Addiction follow-up","Alcohol relapse","Survival","RECRUITING","2026-06-17",{"date":68,"type":35},"2026-06-22",{"date":70,"type":35},"2024-11-21",{"date":72,"type":21},"2030-11-21",{"name":74,"class":42},"University Hospital, Montpellier",16,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":53,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100633328","implementation-facilitation-pilot-for-alcohol-use-disorder-aud-in-alcohol-associated-liver-disease-ald-100633328","NCT07525258","Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)","Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics","Inclusion Criteria:\n\n* Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.\n\nExclusion Criteria:\n\n* Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.",{"count":84,"type":21},30,[55],"The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.",[25,26],[89,90],"Clinicians","Medications for Alcohol Use Disorder","2026-05-05",{"date":93,"type":35},"2026-05-07",{"date":95,"type":35},"2026-04-05",{"date":97,"type":21},"2029-04",{"name":99,"class":42},"Yale University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":53,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":43},"100422476","phase-1-safety-tolerability-and-bioeffects-of-alirocumab-in-non-treatment-seeking-heavy-drinkers-100422476","NCT04781322","Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers","* INCLUSION CRITERIA:\n\n  1. Male or female between the age of 21 and 65 years.\n  2. Ability to provide written informed consent.\n  3. Females: Negative urine pregnancy test, not currently breastfeeding, agree to abstain or use accepted form of contraception including use of oral contraceptives; use of barrier method of contraceptive, such as condoms; use of an approved IUD or other long-acting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively female sexual partner(s).\n\n     Males: Agree to abstain or use accepted form of contraception, such as condoms.\n  4. Current chronic alcohol use, non-treatment seeking heavy drinker (an average of \\>= 20 standard drinks per week for at least 12 weeks).\n\nEXCLUSION CRITERIA:\n\n1. Treatment seeking for alcohol use disorder.\n2. History of a serious hypersensitivity reaction to PCSK9 inhibitors, monoclonal antibodies, or any component of the drug product.\n3. Chronic use of statins within eight weeks of the study to treat hypercholesteremia, or fibrates, with the exception of fenofibrates, within six weeks of the study.\n4. Current\u002Fpast use of PCSK9 inhibitors.\n5. Clinically significant and\u002For unstable cardiovascular-disease over the past 12 months.\n6. Current or prior history of any clinically significant disease, including, fibromyalgia, severe neuropathic pain, seizure disorder, uncontrolled endocrine disease known to influence serum lipids or lipoproteins, hemorrhagic stroke, cancer within the past 5 years (except for adequately treated basal skin cancer, squamous cell skin cancer, or in situ cervical cancer), uncontrolled (defined as Hgb A1c \\>8%) or newly diagnosed (within 3 months prior to screening) diabetes, or any other significant abnormality identified at the time of screening that, in the judgment of the investigator or study clinician, would preclude safe completion of the study.\n7. Positive HIV test or positive Hepatitis B surface antigen (HBsAg), and\u002For positive Hepatitis C antibody (HCV) at screening.\n8. Alanine aminotransferase or aspartate aminotransferase exceeding 5 times the upper limit of normal levels at screening will be excluded. Bilirubin 2x UNL or Creatinine \\> 1.5 mg\u002Fdl at screening will be excluded.\n9. Triglycerides \\> 400mg\u002FdL (\\>4.52 mmol\u002FL) at screening.\n10. Chronic renal failure as estimated by glomerular filtration rate (GFR) \\\u003C 60mL\u002Fmin\u002F1.73 m\\^2 at screening.\n11. Any underlying clinically significant and\u002For unstable acute or chronic liver disease unrelated to alcohol use at screening.\n12. Patients with coagulopathy defined as INR \\>1.5, prothrombin time prolonged by \\> 3s, and\u002For platelets \\\u003C75,000 \u002F mm\\^3 at screening.\n13. Use of any medications that interfere with blood clotting.\n14. Patients with significant hematologic abnormalities.\n15. Significant obesity (Obesity Class III) defined as BMI greater than or equal to 40 at screening.\n16. History of previous bariatric surgery or transplant surgery.\n17. History of plasmapheresis treatment within 2 months prior to screening or plans to undergo plasmapheresis during the study.\n18. Use of the following medications: Any medication that requires intramuscular administration injections. Systemic corticosteroids, unless used as replacement therapy for pituitary\u002Fadrenal disease with a stable regimen for at least 6 weeks prior to screening. Estrogen or testosterone therapy, unless regimen stable for 6 weeks prior to screening visit.\n19. Use of any investigational drugs within 1 month, or five half-lives, whichever is longer, of the study procedures.\n20. Plan to use red yeast rice during the study.\n21. Presence of any current suicidality.\n22. History of epilepsy or alcohol-related seizures in the last 12 months.\n23. Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study, such as psychosis, delirium or acute change of mental status.\n\nFor optional MRI: a) Presence of ferromagnetic objects in the body that may be adversely affected by or contraindicated for MRI, fear of enclosed spaces, or other standard contraindication to MRI, as determined by self-report b) Use of MRI-incompatible intrauterine device (IUD).","21 Years","65 Years",{"count":110,"type":21},100,[112],"PHASE1","Background:\n\nDrinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning\u002Fswelling.\n\nObjective:\n\nTo study the effects of alirocumab in people who drink alcohol.\n\nEligibility:\n\nHealthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week.\n\nDesign:\n\nParticipants will be screened under protocol 14-AA-0181.\n\nParticipants will get alirocumab or a placebo as an injection under the skin.\n\nParticipants will give blood and urine samples. They will have physical exams.\n\nParticipants will have FibroScans . It measures liver and spleen stiffness. Participants will lie on a table. They will expose the lower right and left side of their chest. The machine will send a small vibration to the liver.\n\nParticipants may have magnetic resonance imaging (MRI) scans of the liver. The MRI scanner is shaped like a cylinder. Participants will lie on a table that slides in and out of the scanner. A device called a coil will be placed over their liver.\n\nParticipants will have a Doppler scan and ultrasound. These tests measure blood flow in the body.\n\nParticipants will have an electrocardiogram. It measures heart function.\n\nParticipants will fill out surveys about how they are feeling, their alcohol consumption, and other behaviors. They will complete cognitive tasks on a computer.\n\nParticipants will meet with a clinician. They will discuss the participant s assessment results, patterns of drinking, and possibly stopping or cutting down on drinking.\n\nParticipation will last for 8 weeks. Participants will have 9 study visits.",[58,115],"Heavy Drinking Behavior",[117,118,119,120,121],"Alcohol","Liver","PCSK9","Fatty Liver","Inflammation","2026-04-25",{"date":124,"type":35},"2026-04-28",{"date":126,"type":35},"2021-10-19",{"date":128,"type":21},"2026-12-31",{"name":130,"class":131},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":53,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":43},"100635491","a-digital-pill-system-to-measure-and-support-acamprosate-adherence-in-individuals-with-alcohol-associated-liver-disease-100635491","NCT07553377","A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease","Inclusion Criteria:\n\n* Being treated for AUD\n* Diagnosed with DSM-5 moderate to severe AUD\n* Screens positive ALD utilizing non-invasive blood tests\n* Planned initiation of acamprosate\n\nExclusion Criteria:\n\n* History of hypersensitivity to acamprosate\n* Allergy to magnesium or silver\n* Severe renal impairment (creatinine clearance of 30mL\u002Fmin or less)",{"count":139,"type":21},50,[55],"This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved personalized support and increase medication adherence for people with AUD and ALD.",[25,58,90,143,144],"Behavioral Medicine","Medication Adherence","2026-04-21",{"date":124,"type":35},{"date":148,"type":21},"2027-10",{"date":150,"type":21},"2030-10",{"name":99,"class":42},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":53,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100628741","financial-rewards-for-reducing-alcohol-use-in-patients-with-liver-disease-100628741","NCT07465588","Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease","Randomized Evaluation of Incentives FOR Clinical Effectiveness in Liver Recovery (REINFORCE Trial): A PEth-Based Contingency Management Pilot Randomized Controlled Trial for Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease","REINFORCE","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of alcohol use disorder based on DSM 5 criteria\n* Diagnosis of alcohol associated liver disease or clinically suspected alcohol related liver injury\n* Evidence of recent alcohol use or at risk for alcohol relapse\n* Receiving care in hepatology or liver disease clinic at the participating institution\n* Willingness to undergo serial phosphatidylethanol (PEth) testing using dried blood spot samples\n* Ability to provide informed consent\n* Willingness to participate in the contingency management intervention and follow study procedures\n\nExclusion Criteria:\n\n* Severe cognitive impairment or medical condition that prevents participation in study procedures\n* Active psychosis or severe psychiatric instability that would interfere with participation\n* Current enrollment in another contingency management program targeting alcohol use\n* Medical instability requiring hospitalization at the time of enrollment\n* Inability to communicate in English (if study materials are only available in English)\n* Any condition that, in the opinion of the investigators, would make participation unsafe or interfere with completion of the study",{"count":161,"type":21},90,[55],"This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking. The blood test is called phosphatidylethanol (PEth), which can detect alcohol use over the past three to four weeks. The financial reward program is called contingency management (CM).\n\nThe study has two parts. Part 1 involves one-time interviews and surveys with patients and healthcare providers to understand how a PEth-based CM program could best be delivered in a liver disease clinic. Part 2 is a pilot randomized controlled trial (the REINFORCE Trial) in which participants are randomly assigned to one of two groups: (1) a rewards group that receives escalating financial incentives when PEth results show reduced or no alcohol use, or (2) a monitoring group that receives fixed payments regardless of PEth results. Both groups receive PEth testing and continue their usual medical care. The study will assess whether the rewards program improves alcohol abstinence and reduction at 12 and 24 weeks.'",[25,26,165,166],"Liver Cirrhosis, Alcoholic","Alcohol-Associated Hepatitis",[168,169,170,171,172,173,174,175,176,177],"Contingency Management","Phosphatidylethanol","PEth","Dried Blood Spot","Alcohol Biomarker","Alcohol Abstinence","Hepatology","Liver Disease","Financial Incentives","Behavioral Intervention","2026-03-10",{"date":180,"type":35},"2026-03-12",{"date":182,"type":21},"2026-08-01",{"date":184,"type":21},"2028-06-30",{"name":186,"class":42},"Massachusetts General Hospital",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":195,"targetDuration":4,"studyType":53,"phases":197,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":43},"100452942","phase-2-lgg-supplementation-in-patients-with-aud-and-ald-100452942","NCT05178069","LGG Supplementation in Patients With AUD and ALD","Lactobacillus Rhamnosus GG: A Novel Probiotic Therapy for Treating Alcohol Use Disorder","AUD+ALD","Inclusion Criteria:\n\n1. Breath alcohol concentration (BAC) equal to 0.00 when the participant signs the informed consent document.\n2. Age between 21 and 65 years old (inclusive).\n3. Willingness to receive trial treatment.\n4. Ability to provide informed consent\n5. Understanding that this is not an alcohol treatment study.\n6. Heavy drinking. Men must consume ≥ 20 and women ≥ 14 standardized alcoholic beverages a week for the past 3 months.\n7. Diagnosis of Alcohol Use Disorder using DSM V criteria.\n8. 50 \\\u003CAST\\\u003C400 U\u002FL; AST \\> ALT; and ALT \\\u003C 200 U\u002FL; total bilirubin \\> 1.2 mg\u002FdL\n9. Model for End-Stage Liver Disease: 8 ≤ (MELD) ≤19.\n10. Good health as confirmed by medical history, physical examination, ECG, laboratory tests and vital signs except for liver injury and AUD related history.\n11. Provide contact information for someone who may be able to contact the subject in case of a missed appointment.\n12. . Females of child-bearing potential must not be pregnant and must be using birth control\n\nExclusion Criteria:\n\n1. Current (last 12 months) DSM V diagnosis of dependence on any psychoactive substance other than alcohol or nicotine,\n2. Positive urine drug screen at baseline for any illegal substance other than marijuana,\n3. History of hospitalization for alcohol intoxication delirium, alcohol withdrawal delirium or seizure,\n4. Participation in any research study for alcoholism treatment within 3 months prior to signing the informed consent,\n5. Pharmacological treatment with naltrexone, acamprosate, topiramate, or disulfiram within 1 month prior to randomization,\n6. Lifetime diagnosis based on DSM-V criteria of schizophrenia, bipolar disorder, or other psychosis, eating disorders; current or past year diagnosis of major depression\n7. In the investigators' opinion, moderate to severe risk of suicide (e.g., active plan, or recent attempt in last 6 months),\n8. Current use of psychotropic medications that cannot be discontinued,\n9. Clinically significant medical abnormalities (apart from moderate ALD, MELD≤19),\n10. Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) \\>10, at screening for more than 3 days,\n11. Serious medical diseases, such as cancer, liver cirrhosis, pancreatitis, severe alcohol associated hepatitis, heart chronic failure, chronic kidney failure, chronic intestinal diseases (e.g., Crohn's disease), chronic neurological disorders (e.g., tardive dyskinesia, epilepsy, Parkinson's disease)\n12. History of clinically significant hypotension (e.g., history of lipotimia and\u002For syncopal episodes)\n13. History of adverse reactions to needle puncture,\n14. Obesity (BMI ≥ 33.0 kg\u002Fm2),\n15. Pregnancy; incarceration; inability to provide consent\n16. Signs of systemic infection: Fever \\> 38o C, positive blood or ascites cultures, on appropriate antibiotic therapy for \\> 3 days within 3 days of inclusion\n17. Acute gastrointestinal bleeding requiring \\> 2 units blood transfusion within the previous 2 weeks\n18. Undue risk from immunosuppression: Positive HBsAg; positive skin PPD skin test or history of treatment for tuberculosis; known HIV infection",{"count":196,"type":21},60,[198],"PHASE2","To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH",[25,26],[202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217],"AUD","ALD","AH","TLFB","LTDH","AUDIT","WHO Drinking Level Reduction Criteria","MELD","ALT","AST","ABIC","Total Bilirubin","Heavy Drinking","Drinking Pattern","AUD Domains","Albumin","2025-10-29",{"date":220,"type":35},"2025-10-31",{"date":222,"type":35},"2022-06-01",{"date":224,"type":21},"2027-02-28",{"name":41,"class":42}]